Shire Falls After Announcing Poor Drug Test Results

Drugmaker Shire's shares were down 4.5% early Friday, after the company announced poor results for a potential new treatment for one of its drugs. The Ireland-based company said a two-year phase 3 test of its MMX mesalamine drug to treat patients with a history of diverticulitis "did not meet the primary endpoint in reducing the rate of recurrence." Diverticulitis is a digestive disease in which pouches form, usually in the large intestine, and